PL1680403T3 - Analogi deoksynojirimycyny i ich zastosowania jako inhibitorów glukozyloceramidazy - Google Patents

Analogi deoksynojirimycyny i ich zastosowania jako inhibitorów glukozyloceramidazy

Info

Publication number
PL1680403T3
PL1680403T3 PL04793685T PL04793685T PL1680403T3 PL 1680403 T3 PL1680403 T3 PL 1680403T3 PL 04793685 T PL04793685 T PL 04793685T PL 04793685 T PL04793685 T PL 04793685T PL 1680403 T3 PL1680403 T3 PL 1680403T3
Authority
PL
Poland
Prior art keywords
glucosylceramidase
inhibitors
deoxynojirimycin analogues
deoxynojirimycin
analogues
Prior art date
Application number
PL04793685T
Other languages
English (en)
Inventor
Johannes Maria Franciscus Gerardus Aerts
Original Assignee
Genzyme Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corporation filed Critical Genzyme Corporation
Publication of PL1680403T3 publication Critical patent/PL1680403T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL04793685T 2003-10-29 2004-10-29 Analogi deoksynojirimycyny i ich zastosowania jako inhibitorów glukozyloceramidazy PL1680403T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03078395A EP1528056A1 (en) 2003-10-29 2003-10-29 Deoxynojirimycin analogues and their uses as glucosylceramidase inhibitors
EP04793685.1A EP1680403B1 (en) 2003-10-29 2004-10-29 Deoxynojirimycin analogues and their uses as glucosylceramidase inhibitors

Publications (1)

Publication Number Publication Date
PL1680403T3 true PL1680403T3 (pl) 2017-08-31

Family

ID=34400526

Family Applications (1)

Application Number Title Priority Date Filing Date
PL04793685T PL1680403T3 (pl) 2003-10-29 2004-10-29 Analogi deoksynojirimycyny i ich zastosowania jako inhibitorów glukozyloceramidazy

Country Status (14)

Country Link
US (1) US7528153B2 (pl)
EP (2) EP1528056A1 (pl)
JP (2) JP5016925B2 (pl)
AU (1) AU2004284012B2 (pl)
CA (1) CA2551060C (pl)
CY (1) CY1118191T1 (pl)
DK (1) DK1680403T3 (pl)
ES (1) ES2594356T3 (pl)
HU (1) HUE029637T2 (pl)
IL (1) IL175260A0 (pl)
PL (1) PL1680403T3 (pl)
PT (1) PT1680403T (pl)
SI (1) SI1680403T1 (pl)
WO (1) WO2005040118A1 (pl)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE491451T1 (de) * 2003-10-29 2011-01-15 Genzyme Corp N-(5-adamantane-1-yl-methoxy- pentyl)desoxynojirimycin oder eines pharmazeutischen salzes davon zur verwendung bei der behandlung der insulinresistenz
EP1528056A1 (en) * 2003-10-29 2005-05-04 Academisch Ziekenhuis bij de Universiteit van Amsterdam Deoxynojirimycin analogues and their uses as glucosylceramidase inhibitors
US20060025449A1 (en) * 2004-03-25 2006-02-02 United Therapeutics Use of N-substituted imino sugars for appetite suppression
CA2586761A1 (en) 2004-11-10 2006-05-18 Genzyme Corporation Methods of treating diabetes mellitus
FR2887549B1 (fr) * 2005-06-23 2009-07-10 Centre Nat Rech Scient Nouveaux composes de la famille des iminosucres, leurs utilisations, notamment pour le traitement de maladies lysosomales, ainsi que leur procede de preparation
FR2894482A1 (fr) * 2005-12-14 2007-06-15 Galderma Sa Utilisation d'une composition comprenant une association d'hydroquinone,d'acetonide de fluocinolone et de tretinoine, dans le traitement d'l'hyperpigmentation de la peau suite au psoriasis ou a l'eczema
ATE479696T1 (de) * 2006-04-24 2010-09-15 Amc Amsterdam Verbessertes verfahren zur behandlung von cystischer fibrose
EP2032134B1 (en) 2006-05-09 2015-06-24 Genzyme Corporation Methods of treating fatty liver disease comprising inhibiting glucosphingolipid synthesis
GB0614947D0 (en) * 2006-07-27 2006-09-06 Isis Innovation Epitope reduction therapy
US8304447B2 (en) 2007-05-31 2012-11-06 Genzyme Corporation 2-acylaminopropoanol-type glucosylceramide synthase inhibitors
GB0712494D0 (en) 2007-06-27 2007-08-08 Isis Innovation Substrate reduction therapy
KR20160085917A (ko) 2007-10-05 2016-07-18 젠자임 코포레이션 세라마이드 유도체로 다낭성 신장질환을 치료하는 방법
US8497122B2 (en) 2008-04-11 2013-07-30 Washington University Biomarkers for Niemann-pick C disease and related disorders
WO2010014554A1 (en) 2008-07-28 2010-02-04 Genzyme Corporation Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease
US8309593B2 (en) 2008-10-03 2012-11-13 Genzyme Corporation 2-acylaminopropoanol-type glucosylceramide synthase inhibitors
PL3395372T3 (pl) * 2009-02-20 2022-07-25 EnhanX Biopharm Inc. Układ do dostarczania leków na bazie glutationu
CA2793276A1 (en) * 2009-03-27 2010-09-30 Zacharon Pharmaceuticals, Inc. Ganglioside biosynthesis modulators
WO2011070407A1 (en) * 2009-12-07 2011-06-16 University Of Oxford N-substituted deoxynojirimycin compounds for use in inhibiting osteoclastogenesis and/or osteoclast activation
MX373121B (es) 2010-05-14 2020-04-30 Dana Farber Cancer Inst Inc Composiciones y metodos para el tratamiento de leucemia.
CA2799381A1 (en) 2010-05-14 2011-11-17 Dana-Farber Cancer Institute, Inc. Male contraceptive compositions and methods of use
US8981083B2 (en) 2010-05-14 2015-03-17 Dana Farber Cancer Institute, Inc. Compositions and methods for treating neoplasia, inflammatory disease and other disorders
ES2371398B1 (es) * 2010-06-04 2013-05-20 Bioglane, S.L.N.E. Uso de un iminoazúcar como inhibidor de la adherencia a células epiteliales.
EP2533051A1 (en) * 2011-06-06 2012-12-12 Centogene GmbH Method for the diagnosis of Gaucher's disease
EP2885637B1 (en) * 2012-08-15 2016-11-30 The Procter & Gamble Company Use of human ex vivo skin model in a method of identifying modulators of skin inflammation
KR20150128899A (ko) * 2013-03-15 2015-11-18 유니터 바이롤로지, 엘엘씨 항박테리아 화합물
US20160075651A1 (en) * 2013-05-02 2016-03-17 Unither Virology, Llc Glycolipid inhibition using iminosugars
CN106456664A (zh) * 2013-05-02 2017-02-22 牛津大学之校长及学者 脂质组学生物标志物
BR112016001457A2 (pt) 2013-07-25 2017-08-29 Dana Farber Cancer Inst Inc Inibidores de fatores de transcrição e usos dos mesmos
KR20160072261A (ko) 2013-11-08 2016-06-22 다나-파버 캔서 인스티튜트 인크. 브로모도메인 및 엑스트라-말단 (bet) 단백질 저해제를 이용한 암 치료를 위한 조합 요법
WO2015117087A1 (en) 2014-01-31 2015-08-06 Dana-Farber Cancer Institute, Inc. Uses of diazepane derivatives
MX2016009974A (es) 2014-01-31 2016-10-31 Dana Farber Cancer Inst Inc Derivados de diaminopirimidina bencensulfona y sus usos.
RU2722179C2 (ru) 2014-02-28 2020-05-28 Тэнша Терапеутикс, Инк. Лечение состояний, ассоциированных с гиперинсулинемией
ES2895490T3 (es) 2014-03-27 2022-02-21 Acad Medisch Ct Iminoazúcares N-(5-(bifen-4-ilmetiloxi)pentil)-sustituidos como inhibidores de glucosilceramida sintasa
WO2016022970A1 (en) 2014-08-08 2016-02-11 Dana-Farber Cancer Institute, Inc. Dihydropteridinone derivatives and uses thereof
EP3177626A4 (en) 2014-08-08 2017-12-27 Dana Farber Cancer Institute, Inc. Diazepane derivatives and uses thereof
UA122130C2 (uk) 2014-10-27 2020-09-25 Тенша Терапеутікс, Інк. Інгібітори бромодомену
US10702527B2 (en) 2015-06-12 2020-07-07 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
US11306105B2 (en) 2015-09-11 2022-04-19 Dana-Farber Cancer Institute, Inc. Cyano thienotriazolodiazepines and uses thereof
JP2018526424A (ja) 2015-09-11 2018-09-13 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド アセトアミドチエノトリアゾロジアゼピンおよびこれらの使用
CR20180336A (es) 2015-11-25 2018-08-06 Dana Farber Cancer Inst Inc Inhibidores de bromodominio bivalentes y usos de los mismos
EP3318277A1 (en) 2016-11-04 2018-05-09 Institut du Cerveau et de la Moelle Epiniere-ICM Inhibitors of glucosylceramide synthase for the treatment of motor neuron diseases
WO2020185675A1 (en) * 2019-03-08 2020-09-17 University Of Virginia Patent Foundation Compositions and methods for modulating viral infections by regulating glucosylceramides
EP4146623A4 (en) * 2020-05-07 2024-05-01 Alectos Therapeutics Inc. Non-lysosomal glucosylceramidase inhibitors and uses thereof
WO2022227287A1 (zh) * 2021-04-25 2022-11-03 中南大学 Dnj及其衍生物在制备预防和/或治疗肺动脉高压药物中的应用
CN118459393B (zh) * 2024-04-29 2025-11-28 中国科学院成都生物研究所 一类具有α-葡萄糖苷酶抑制活性的D-木糖衍生物及制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2504000B2 (ja) 1986-09-02 1996-06-05 日本新薬株式会社 グルコシルモラノリン誘導体
WO1998002161A1 (en) 1996-07-15 1998-01-22 Universiteit Van Amsterdam Deoxynojirimycin derivatives and their uses as glucosylceramidase inhibitors
BR9902585A (pt) 1999-02-11 2000-09-26 Claudio Cerqueira Lopes Um novo processo de sìntese de aza-açúcares com atividade biológica
GB0100889D0 (en) * 2001-01-12 2001-02-21 Oxford Glycosciences Uk Ltd Compounds
US6235737B1 (en) 2000-01-25 2001-05-22 Peter Styczynski Reduction of hair growth
US20040204379A1 (en) 2000-06-19 2004-10-14 Cheng Seng H. Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
JP4585851B2 (ja) * 2002-07-17 2010-11-24 アクテリオン ファーマシューティカルズ リミテッド グルコシルセラミドシンターゼの阻害剤としてのピペリジントリオール誘導体
EP1534676B1 (en) * 2002-07-17 2012-09-12 Actelion Pharmaceuticals Ltd. Piperidinetriol derivatives as inhibitors of glycosylceramide synthase
GB0229476D0 (en) 2002-12-17 2003-01-22 Oxford Glycosciences Uk Ltd Novel process
ATE491451T1 (de) * 2003-10-29 2011-01-15 Genzyme Corp N-(5-adamantane-1-yl-methoxy- pentyl)desoxynojirimycin oder eines pharmazeutischen salzes davon zur verwendung bei der behandlung der insulinresistenz
EP1528056A1 (en) * 2003-10-29 2005-05-04 Academisch Ziekenhuis bij de Universiteit van Amsterdam Deoxynojirimycin analogues and their uses as glucosylceramidase inhibitors
WO2005063706A1 (en) 2003-12-23 2005-07-14 Macrozyme Dnm B.V. Synthesis of nojirimycins
EP3782655A1 (en) 2005-05-17 2021-02-24 Amicus Therapeutics, Inc. A method for the treatment of pompe disease using 1-deoxynojirimycin and derivatives

Also Published As

Publication number Publication date
ES2594356T3 (es) 2016-12-19
JP2007509926A (ja) 2007-04-19
HUE029637T2 (en) 2017-03-28
JP5730808B2 (ja) 2015-06-10
AU2004284012B2 (en) 2010-06-17
EP1680403A1 (en) 2006-07-19
US7528153B2 (en) 2009-05-05
WO2005040118A1 (en) 2005-05-06
CY1118191T1 (el) 2017-06-28
PT1680403T (pt) 2016-09-07
CA2551060A1 (en) 2005-05-06
EP1528056A1 (en) 2005-05-04
US20070066581A1 (en) 2007-03-22
JP2012180353A (ja) 2012-09-20
CA2551060C (en) 2012-08-28
SI1680403T1 (sl) 2017-01-31
DK1680403T3 (en) 2016-09-26
JP5016925B2 (ja) 2012-09-05
AU2004284012A1 (en) 2005-05-06
EP1680403B1 (en) 2016-06-29
IL175260A0 (en) 2006-09-05

Similar Documents

Publication Publication Date Title
IL175260A0 (en) Deoxynojirimycin analogues and their uses as glucosylceramidase inhibitors
AU2003298514A8 (en) Methods and compositions using cholinesterase inhibitors
PL372814A1 (pl) Tiazolidyno-4-karbonitryle i analogi oraz ich zastosowanie jako inhibitory dipeptydylo-peptydaz
AP2089A (en) Compositions and methods for combination antiviraltherapy
EP1633718A4 (en) COMPOSITIONS AND METHODS FOR INHIBITING TGF-S
EG25482A (en) Inhibitors
GB0411940D0 (en) Methods and compositions
IL187620A0 (en) 17??-hsd1 and sts inhibitors
SI1592686T1 (sl) Inhibitorji giraze in njihova uporaba
AU2003299034A8 (en) Transdermal compositions
AU2003256805A8 (en) Compounds compositions and methods
AU2003232848A8 (en) Phenylaminopyrimidines and their use as rho-kinase inhibitors
AU2003275268A8 (en) Hemostatic compositions and methods
EP1532133A4 (en) NF-: B INHIBITORS
EP1684771A4 (en) COMPOSITION AND METHOD
ZA200502843B (en) Methods and compositions for providing glutamine
AU2003299901A8 (en) Thrombin inhibitors
EP1765373A4 (en) OZONIZED PHARMACEUTICAL COMPOSITION AND METHOD THEREOF
AU2003275240A8 (en) Methods and compositions for soluble cpg15
AU2003268078A8 (en) Levothyroxine compositions and methods
AU2003222258A8 (en) Inhibitors for use in hemostasis
AU2003245524A8 (en) Cryosurgery compositions and methods
AU2003298035A8 (en) Compositions and methods for inhibiting malaria protease falcipain-2
AU2003238948A8 (en) Caspase-1 inhibitors and methods for their use
GB0330062D0 (en) Compositions and methods